Efficacy of Brincidofovir as prophylaxis against HSV and VZV in hematopoietic cell transplant recipients

Autor: Dionysios Neofytos, Yeon Joo Lee, Genovefa A. Papanicolaou, Ann A. Jakubowski, Seong Jin Kim, Esperanza B. Papadopoulos, Yao-Ting Huang, Leslie Cheteyan
Jazyk: angličtina
Rok vydání: 2018
Předmět:
0301 basic medicine
Male
Herpesvirus 3
Human
medicine.medical_treatment
viruses
medicine.disease_cause
Antibiotic Prophylaxis/methods
chemistry.chemical_compound
0302 clinical medicine
Simplexvirus
030212 general & internal medicine
Simplexvirus/drug effects/isolation & purification
Child
Varicella Zoster Virus Infection/epidemiology/prevention & control/virology
ddc:616
Viral culture
Hematopoietic Stem Cell Transplantation
virus diseases
Immunosuppression
Middle Aged
Infectious Diseases
Treatment Outcome
Child
Preschool
Female
Cidofovir
medicine.drug
Adult
Organophosphonates/pharmacology/therapeutic use
Congenital cytomegalovirus infection
Organophosphonates
Brincidofovir
Herpesvirus 3
Human/drug effects/isolation & purification
Virus
Article
03 medical and health sciences
Cytosine
Young Adult
medicine
Humans
Hematopoietic Stem Cell Transplantation/adverse effects
Aged
Retrospective Studies
Transplantation
business.industry
Infant
Herpes Simplex
biochemical phenomena
metabolism
and nutrition
Antibiotic Prophylaxis
medicine.disease
Virology
030104 developmental biology
Herpes simplex virus
chemistry
Concomitant
Varicella Zoster Virus Infection
Cytosine/analogs & derivatives/pharmacology/therapeutic use
Herpes Simplex/epidemiology/prevention & control/virology
business
Zdroj: Transplant Infectious Disease, Vol. 20, No 6 (2018) P. e12977
ISSN: 1398-2273
Popis: BACKGROUND: Allogeneic hematopoietic cell transplant (HCT) recipients are at risk for herpes simplex virus (HSV) and varicella-zoster virus (VZV) infections. Routine prophylaxis with acyclovir is recommended during periods of immunosuppression. Brincidofovir (BCV, CMX001), a lipid conjugate of cidofovir, is active in vitro activity against HSV/VZV, but has not been formally studied for HSV/VZV prophylaxis. We report our clinical experience of BCV for HSV/VZV prophylaxis in HCT recipients. METHODS: This was a retrospective review of 30 hematopoietic cell transplant (HCT) recipients between 8/2010 and 8/2015 who received BCV doses not to exceed 200mg/week for adults/adolescents and 4mg/kg/week for pediatric (
Databáze: OpenAIRE
Externí odkaz: